Vesrisante Technology

2

This presentation contains certain forward-looking statements. Thesestatements relate to future events or future performance and reflectmanagement’s expectations and assumptions regarding growth,results of operations, performance and business prospects andopportunities. Such forward-looking statements reflectmanagement’s current beliefs and are based on informationcurrently available to management.

A number of factors could cause actual events to differ materially. Inevaluating these statements, prospective purchasers shouldspecifically consider various risks as more fully outlined in theprospectus, a copy of which can be obtained online atwww.sedar.com.

Forward Looking Statements

2

3

Skin cancer strikes 1 in 5 in the U.S.1

It is the most common form of cancer

40-50% of Americans who live to 65 expected to get skin cancer 2

Melanoma kills one person every hour in the US 3

Melanoma is the #1 cancer killer of women 25-30 4

Incidence of melanoma rising faster than any other cancer 5

- Howard Rogers, Dermatologist, Lead on Medicare research“There’s an epidemic of skin cancer”

3

Melanoma is DeadlyAccounts for 75% of skin cancer deaths6

4

Early detection vital to saving lives

0

20

40

60

80

100 95% Melanoma Five Year Survival Rate by Tumor Stage 6

15%

Stage I Stage II Stage III Stage IV

5

2 million Americans get skin cancer each year 7

Treating melanoma alone costs $1.5 billion annually in the U.S. 8

Advanced stage melanoma 22 times more costly to treat than early stage

Early detection would save billions of dollars

5.011.0 13.7

22.5 24.3

35.4 38.3

105.5110.1

Cost of Treating Melanomaby Tumor Stage (per patient) 9

Early Stage Late Stage

($ US thousands)

6

Primary diagnosis done by GPs with varying levels of experience

Full body examinations seldom conducted

33.8% sensitivity for melanoma for GPs 10

› Squamous Cell Carcinoma – 41.1%

› Basal Cell Carcinoma – 63.9%

Biopsies invasive and costly

› Permanent scarring

~80% of biopsies test negative 11

Current skin cancer detection methods limited

Clinical Diagnosis

Punch Biopsy

Histological Diagnosis

7

Detects melanoma with 97% accuracy vs. 33.8% for primary clinical diagnosis

Developed by BC Cancer Agency and UBC

Patented technology

Exclusively licensed to Verisante Technology, Inc.

Initial Focus: Early detection of skin cancerBreakthrough early stage cancer detection system

All forms of

Skin Cancer

Gastrointestinal,

Lung, and Cervical

Cancers

8

Skin cancer: Verisante AuraTM

Highly automated detection process

Near Infrared Raman Spectroscopy

Handheld probe scansfor 21 biomarkers inan instant

Rapid speed enablesfull body scans

Provides data on chemical composition of skin based on molecular vibrations

Differentiates betweenmalignant and benign tissue

Pathology on every lesion scanned

9


Highly automated detection process

Safe, Non-invasive, Fast

Real time results97% accurate for melanoma91% for other skin cancers

Increased survival rates

Reduced treatment costs

No unnecessary biopsies

Reduced waiting times

10

6 year clinical study at Vancouver General Hospital’s Skin Care Center

Focused on differentiating cancerous lesions from benign lesions

1,000 skin lesions scanned

Preliminary results published in 2008 based on 274 lesions 12


Proven in clinical trials by the BC Cancer Agency

Melanoma

97% sensitivity“Percentage identified”

78% specificity“Confirmed by biopsy”

Cancerous and Precancerous Lesions

91% sensitivity“Percentage identified”

75% specificity“Confirmed by biopsy”

11

Verisante Aura™

Proven technology

Detects all skin cancers

97% Sensitivity; 78% Specificity for melanoma

Measures 21 biomarkers

Virtually instant scan

Non-invasive

Tiny Probe

Inexpensive disposable covers

Superior technology over competing systems

Scibase Inc.

• Electrical Impedance Spectroscopy• 98% sensitivity; specificity < 5% • Slightly invasive• 5 minutes per lesion• Large probe/expensive disposables

Mela Sciences

• Computerized Imaging Technology• FDA Panel recommends approval by narrow margin• Key Concern: too many false positives• 98% sensitivity; 9.5% specificity• Large probe

Lucid Inc.

• Confocal Microscopy• 10-20 min. per lesion• Dermatologist required• Large probe

12

Clinical studies underway at VGH for early detection of lung & colon cancer

Lung Cancer 13

World’s #1 cancer killer with

1.4 million deaths/year

Colon Cancer

#2 deadliest cancer in U.S.

Cervical Cancer

World’s #2 cause of cancer

deaths among women

Verisante CoreTM

Endoscopic system enables detection of other cancers

13

Dr. Branko PalcicPh.D.

• Honorary Professor, Dept. of Pathology and Laboratory Medicine, UBC

• Founder, Cancer Imaging and Technology Departments, BC Cancer Agency

• Co-inventor of LIFE-Lung device, used in over 150 major medical centers world-wide

• Friesen-Rygiel Award for Outstanding Canadian Academic Discovery (1999)

• King George V Silver Jubilee Cancer Research Fellow

Dr. Haishan ZengPh.D.

• Senior Scientist, Integrative Oncology Dept. BC Cancer Agency

• Associate Professor, Dermatology and Skin Science, University of British Columbia

• Co-inventor - Verisante™ technology

Focused on developing systems for the early detection of cancerStrong scientific pedigree

14

Dr. David McLeanMD, FRCPC

• Professor, Dept. of Dermatology and Skin Science, UBC

• President, Cancer Prevention Institute of Canada

• Former President, Canadian Dermatology Association


Dr. Harvey LuiMD, FRCPC

• Professor and Head, Dept. of Dermatology and Skin Science, UBC

• Former Clinical Fellow, Massachusetts General Hospital, Harvard Medical School

• University Killam Prize (2001)


Focused on developing systems for the early detection of cancerStrong scientific pedigree

15


Clear regulatory pathway to commercialization

2010 2011 2012 2013 2014 2015

Marketing and Sales (Canada)

Marketing and Sales (EU, South Africa, Australia)

Marketing and Sales (USA)

Production Prototype & Health Canada Approval

CE Mark

Clinical Study Prep.

ApprovalClinical StudyUSA

16


Significant market potential with multiple end users

Canada

USA

EU

South Africa

AustraliaNZ

Initial Geographic MarketsRecurring revenue from sale of disposable probe shields

Staged Rollout Strategy

STEP 1

Early adopters~32,000 Dermatologists

STEP 2

Innovators~950,000 General Practitioners

STEP 3

Skin Care ClinicsOncology and Imaging Clinics

HMOs

17

Will drive broader market acceptanceInitial focus on early adopters and innovators

0

400

800

1200

1600

2000

Yr. 1 Yr. 2 Yr. 3 Yr. 4 Yr. 5

Targeting 14% penetration by year 5 Dermatologists

Canada, European Union, South Africa, Australia, New Zealand

United States

18

Will drive broader market acceptanceInitial focus on early adopters and innovators

General Practitioners

Canada, European Union, South Africa, Australia, New Zealand

United States

0

5000

10000

15000

20000

25000

30000

35000

Yr. 1 Yr. 2 Yr. 3 Yr. 4 Yr. 5

Targeting 6% penetration by year 5

19

Thomas BraunBA, JD, LLM – Chief Executive Officer

• Public company experience

• Extensive experience in executing M&As and raising capital

• Advised high tech companies on international business transactions

• Expertise in technology licensing

• Member California Bar Association

Anna TrinhB.Comm, LLB – Chief Financial Officer and Corporate Counsel

• Experience in counseling companies on regulatory and compliance filings

• M&A and financial transaction experience

• Practiced corporate securities law in private practice

Focus: controlling costs, accelerating product development & regulatory approval processExperienced management

20

Joe BiegelBS, MS (Medical Imaging)

• Vice-President, Product Management & Marketing

• McKesson Medical Imaging Group

• Senior positions with Agfa Healthcare, Hewlett Packard, Polaroid Medical Imaging

Karen BoodramBSc, MBA

• Vice-President, Business Development, SemBiosys

• Former Life Sciences Analyst, PI Financial

• More than 25 years healthcare experience

• Ten years with Novartis

Strong, independent Board of Directors

Chris DennisMBA

• Former President, Comcare Health Services

• Senior positions with AngiotechPharmaceuticals, Johnson & Johnson / Ortho Neutrogena

Jake ThiessenPh.D.

• Professor Emeritus, University of Toronto

• Founding Director, School of Pharmacy and Health Sciences Campus, University of Waterloo

21

Share Capital

Common Shares 46,188,117

Common Shares (held by Founders) 14,700,000

Total Common Shares Outstanding 60,888,117

Warrants 17,568,600

Incentive Stock Options 3,545,000

Fully Diluted Share Capital 82,001,717

22

Market Comparables

Company Market Capitalization

MELA Sciences, Inc. (NASDAQ: MELA) $93,000,000

Novadaq (TSX: NDQ) $126,000,000

ALI Technologies Inc. *Sold to McKesson (NYSE: MCK) in 2002 for $530 Million

$530,000,000

23

Breakthrough early stage skin cancer detection device

Patented technology with exclusive worldwide license from BC Cancer Agency

Clear regulatory pathway to commercialization with significant market potential

Endoscopic device for early stage detection of lung, colon and cervical cancers in clinical trials

Strong scientific pedigree and experienced management

Summary

24

ReferencesEnd Notes

1. American Cancer Society. Cancer Facts & Figures 2009

2. National Cancer Institute. Cancer Trends Progress Report 2007, Update April 2008

3. American Cancer Society. Cancer Facts and Figures 2009

4. Melanoma Research Foundation

5. National Cancer Institute. SEER Cancer Statistics Review, 1975-2004

6. National Center for Chronic Disease Prevention and Health Promotion

7. Rogers HW, Weinstock MA, et al. Incidence Estimate of Non Melanoma Skin Cancer in the U.S., 2006, Archives of Dermatology 2010

8. National Cancer Institute. Cancer Trends Progress Report 2007

9. Doru Traian Alexandrescu. Melanoma Costs: A Dynamic Model Comparing Estimated Overall Costs of Various Clinical Stages,

Dermatology Online Journal, Nov 2009

10. Heal CF, Raasch BA, Buettner PG, Weeden D. Accuracy of Clinical Diagnosis of Skin Lesions, British Journal of Dermatology 2009

11. Jones TP, Boiko PE, Piepkorn MW. Skin biopsy indications in primary care practice: a population-based study. JABFP 1996; 9:397–404.

12. Raman Spectroscopy for In Vivo Tissue Analysis and Diagnosis, Instrument Development to Clinical Applications, Journal of

Innovation in Optical Health Sciences 2008

13. Cancer Research UK

14. National Cancer Institute. SEER Database, 1998 – 2000

15. Melamed MR, Flehinger BJ, Zamen MB, et al. Screening for early lung cancer: results of the Memorial Sloan-Kettering study In New

York. Chest 86:44-53, 1984.

16. Cortese DA, Pairolero PC, Bergstralh EJ, et al. Roentgenographically occult lung cancer. A ten-year experience. J Thorac Cardiovasc

Surg 86:373—80, 1983

25

Thank you

Lifestyle

Vesrisante Technology